Work

Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia

Year: 2018

Type: article

Abstract: with severe CRS; these costs are equivalent to the costs of many of today's most expensive medications.Moreover, under the proposed outcomes-based pricing arrangement, nondrug costs are not refunded for patients who do not demonstrate a response to treatment.Payers and the public must understand that only the costs borne by the manufacturer, but not the total costs of CAR-T immunotherapy, will be reimbursed for those who display no treatment response.As the number of patients eligible for CAR-T immunotherapy and other expensive therapies increase, accurately measuring and accounting for the associated nondrug costs will be important when assessing the treatment's true costs and value and when negotiating pricing arrangements.

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2018.0818